New combo therapy aims to save more breasts in High-Risk cancer

NCT ID NCT02806258

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether adding a short course of focused radiation to standard chemotherapy before surgery could improve outcomes for women with aggressive breast cancers. The trial enrolled 362 patients with luminal B or triple-negative breast cancer that was too large for initial breast-conserving surgery. Participants received either chemotherapy alone or chemotherapy plus accelerated partial breast irradiation, followed by surgery. The study was terminated early, so the full impact on complete response rates and breast conservation remains uncertain.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

chemotherapy (anthracycline and/or taxane based) and accelerated partial breast irradiation

What this could lead to

If successful, this approach could increase the chance of a complete response and allow more women to have breast-conserving surgery instead of mastectomy.

What could go wrong

The trial was terminated early, so results are limited. Adding radiation before surgery may increase side effects without clear benefit.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUMINAL B BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm luminal B breast carcinoma triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • AP-HP Henri mondor

    Paris, France

  • CHI Créteil

    Créteil, France

  • CHU Avicenne

    Paris, France

  • CHU de Grenoble

    Grenoble, 38043, France

  • H. Hartmann Institute of Radiotherapy and Radiosurgery

    Paris, France

  • Tenon hospital

    Paris, France